Resource Center
Resource Center
Introducing the third edition of CHAI’s HIV Mid-Year Market Memo, a brief that that covers the latest trends in the HIV space in low- and middle-income countries since the publication of CHAI’s annual HIV Market Report in September 2018. Read the HIV Mid-Year Market Memo here. Read the 2018 HIV Market Report.
Read moreIn 2019, updates to historical datasets were made upon consultation with relevant current suppliers, including the addition of a new supplier’s data. Please find the most up-to-date report here. The 2018 Family Planning Market Report can be found below.
Read moreThe 2017 Annual Report looks back at what we have accomplished over the year, as well as toward the goals that we have set for each of our programs over the next five to 10 years.
Read moreA clear understanding of the complex, ever-changing antiretroviral (ARV) and diagnostic markets in low- and middle-income countries is critical for all stakeholders in the HIV space. To address this need, CHAI publishes an annual HIV market report for public consumption based on aggregated market intelligence from our programmatic work in over 30 countries. We are...
Read moreCHAI’s HIV Market Report provides a global perspective on the ARV marketplace in low- and middle-income countries in 2017 and outlines CHAI’s expectations on how the market will evolve over the next five years. Read the report here: 2018 HIV Market Report
Read moreIntroducing the second edition of CHAI’s HIV Mid-Year Market Memo, an informational brief that covers the latest trends in the HIV space in low- and middle-income countries (LMICs) since the publication of CHAI’s annual ARV Market Report in September 2017. See the HIV Mid-Year Market Memo here. See the 2017 ARV Market Report here.
Read moreAs low- and middle-income countries (LMICs) set their sights on the global elimination of hepatitis C virus (HCV) by 2030, adoption of WHO recommendations for diagnosis and improved access to testing will be critical. We believe that better market intelligence will lower supply- and demand-side barriers and help to eliminate HCV for good. This is...
Read moreCHAI supports national governments to expand high-quality care and treatment to people living with HIV/AIDS. CHAI negotiates reduced prices for antiretroviral (ARVs) on behalf of members of its procurement consortium. See the 2017 CHAI ARV Reference Price List here.
Read moreYears of experience show that licensing is highly effective for ensuring that many more people in developing countries can access life-saving HIV medicines. CHAI and Access to Medicine Foundation have published a paper outlining best practice licensing models that originator companies should employ to enable widespread access to their drugs. It also explores how these...
Read moreIn 2019, updates to historical datasets were made upon consultation with relevant current suppliers, including the addition of a new supplier’s data. Please find the most up-to-date report here. The 2017 Family Planning Market Report can be found below.
Read more